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As part of an ongoing study on environmental
agents and male reproductive health, male
partners of subfertile couples who presented to
the Vincent Burnham Andrology Laboratory
at Massachusetts General Hospital (MGH;
Boston, MA) provided a semen and a spot
urine sample at their clinic visits. Men also
completed a questionnaire including informa-
tion on lifestyle factors, medical history, and
medication use. The results of the relationship
between phthalates and testicular function have
been reported elsewhere (Duty et al. 2003a,
2003b). In this article we report on medication
use as a likely source of dibutyl phthalate
(DBP) exposure in one of the subjects from
this ongoing study who had unusually high
urinary concentrations of monobutyl phthalate
(MBP), the primary metabolite of DBP.
The study was approved by the Harvard
School of Public Health and MGH Human
Subjects Committees. Information on medica-
tion use was collected with a nurse-adminis-
tered questionnaire at the time of the visit to
the clinic to provide the semen and urine sam-
ples. The subject was asked, “Have you recently
(past few weeks) taken any medications? If yes,
please provide types and date(s) last taken.”
Several phthalate monoesters were meas-
ured in a single spot urine sample collected in a
sterile specimen cup. The analytical approach
has been described in detail elsewhere (Blount
et al. 2000a; Silva et al. 2003). Briefly, the
determination of phthalate metabolites in
urine involved enzymatic deconjugation of the
metabolites from the glucuronidated form,
solid-phase extraction, separation with HPLC,
and detection by tandem mass spectrometry.
Detection limits were in the low nanogram
per milliliter range. 13C4-labeled internal stan-
dards were used to increase the precision of
measurements. One method blank, two qual-
ity control samples (human urine spiked with
phthalates), and two sets of standards were
analyzed along with every 21 unknown urine
samples. Analysts at the Centers for Disease
Control and Prevention (CDC; Atlanta, GA)
were blind to all information concerning the
subjects. Creatinine adjustment was used to
correct for urine dilution.
The case patient was in his early thirties
and had an unremarkable occupational history,
without any known workplace exposures. He
had a medical history of ulcerative colitis and
reported taking Asacol (Proctor & Gamble,
Cincinnati, OH), which contains the active
ingredient mesalamine (5-amino-2-hydroxy-
benzoic acid), also known as 5-ASA or
mesalazine in Europe. He took twelve 400 mg
Asacol tablets daily during the 3 months before
the collection of his urine sample. Although
not fully understood, the anti-inflammatory
action of mesalamine is thought to be through
blocking cyclo-oxygenase and inhibiting
prostaglandin production in the colon (Proctor
& Gamble Pharmaceuticals 2000; Schroeder
2002). The Asacol delayed-release tablets are
coated with methacrylic acid copolymer B
(Eudragit-S; Rhöm GmbH & Co. KG,
Darmstadt, Germany), which dissolves at
≥ pH 7, releasing mesalamine in the terminal
ileum and beyond for topical anti-inﬂamma-
tory action in the colon. Other inactive ingre-
dients in Asacol tablets are colloidal silicon
dioxide, edible black ink, iron oxide red, iron
oxide yellow, lactose, magnesium stearate,
polyethylene glycol, povidone, sodium starch
glycolate, talc, and DBP (Proctor & Gamble
Pharmaceuticals 2000). 
The patient’s urinary MBP concentration
was 16,868 ng/mL (6,180 µg/g creatinine),
whereas monoethyl phthalate (MEP), mono-
2-ethylhexyl phthalate (MEHP), and
monobenzyl phthalate (MBzP) concentra-
tions were 443.7 ng/mL (162.6 µg/g creati-
nine), 3.0 ng/mL (1.1 µg/g creatinine), and
9.3 ng/mL (3.4 µg/g creatinine), respectively.
Discussion
There is scientific and public concern about
potential human health risks from exposure to
phthalates, diesters of phthalic acid. These
concerns stem from studies showing that a
large proportion of the U.S. general popula-
tion are exposed to phthalates (Blount et al.
2000b; CDC 2003), as well as from animal
studies consistently showing that some phtha-
lates are developmental and reproductive
toxicants (Agarwal et al. 1985; Cater et al.
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Phthalates are a group of multifunctional chemicals used in consumer and personal care products,
plastics, and medical devices. Laboratory studies show that some phthalates are reproductive and
developmental toxicants. Recently, human studies have shown measurable levels of several phthalates
in most of the U.S. general population. Despite their widespread use and the consistent toxicologic
data on phthalates, information is limited on sources and pathways of human exposure to phthalates.
One potential source of exposure is medications. The need for site-speciﬁc dosage medications has
led to the use of enteric coatings that allow the release of the active ingredients into the small intes-
tine or in the colon. The enteric coatings generally consist of various polymers that contain plasticiz-
ers, including triethyl citrate, dibutyl sebacate, and phthalates such as diethyl phthalate (DEP) and
dibutyl phthalate (DBP). In this article we report on medications as a potential source of exposure to
DBP in a man who took Asacol [active ingredient mesalamine (mesalazine)] for the treatment of
ulcerative colitis. In a spot urine sample from this man collected 3 months after he started taking
Asacol, the concentration of monobutyl phthalate, a DBP metabolite, was 16,868 ng/mL
(6,180 µg/g creatinine). This concentration was more than two orders of magnitude higher than the
95th percentile for males reported in the 1999–2000 National Health and Nutrition Examination
Survey (NHANES). The patient’s urinary concentrations of monoethyl phthalate (443.7 ng/mL,
162.6 µg/g creatinine), mono-2-ethylhexyl phthalate (3.0 ng/mL, 1.1 µg/g creatinine), and
monobenzyl phthalate (9.3 ng/mL, 3.4 µg/g creatinine) were unremarkable compared with the
NHANES 1999–2000 values. Before this report, the highest estimated human exposure to DBP was
more than two orders of magnitude lower than the no observable adverse effect level from animal
studies. Further research is necessary to determine the proportional contribution of medications, as
well as personal care and consumer products, to a person’s total phthalate burden. Key words: bio-
markers, environmental health, medications, phthalates, reproductive health. Environ Health
Perspect 112:751–753 (2004). doi:10.1289/ehp.6804 available via http://dx.doi.org/ [Online
29 January 2004]
Environmental Medicine Case Report1977; Foster et al. 1980; Mylchreest et al.
1999, 2000; Park et al. 2002; Sjoberg et al.
1986). Two recent reports on the levels of
phthalate monoester metabolites in urine sam-
ples collected for the third U.S. National
Health and Nutrition Examination Survey
(NHANES III) (Blount et al. 2000a) and
NHANES 1999–2000 (CDC 2003) showed
that four phthalate metabolites, MEP, MEHP,
MBP, and MBzP, were present in more than
75% of subjects sampled. Monoester phthalate
metabolites were measured because of potential
sample contamination from the parent diester
and because the metabolites are considered the
biologically active toxicant (Li et al. 1998; Peck
and Albro 1982). The preferred measure of
phthalate exposure is urinary phthalate
monoester metabolite levels because they repre-
sent an integrative measure of exposure to
phthalates from the multiple sources and
routes of exposure (CDC 2003; Silva et al.
2003).
Phthalates are a family of multifunctional
chemicals that are used in countless and
diverse products. They are used to hold color
and scent in consumer and personal care
products; as solvents in paints, glue, insect
repellents, lubricants, and adhesives; and to
soften a wide range of plastics, including
medical products such as polyvinyl chloride
(PVC) blood products and intravenous bags,
as well as dialysate bags and tubing [Agency
for Toxic Substances and Disease Registry
(ATSDR) 1995, 2000, 2001; Nassberger
et al. 1987]. Diethyl phthalate (DEP), dibutyl
phthalate (DBP), and butyl benzyl phthalate
(BBzP) are principally used in personal care
products, such as body lotions, gels, sham-
poos, and deodorants (ATSDR 1995, 2001).
Several phthalates, including DBP, have U.S.
Food and Drug Administration (FDA)
approval as inert ingredients in medications
and as indirect food additives for uses as adhe-
sives and components of coatings in food
packaging and processing materials that are in
contact with food (U.S. FDA 2000, 2003).
As a result, phthalates may be ingested in
medications and foods (Castle et al. 1990;
Page and Lacroix 1995). Phthalates such as
DBP, BBzP, and di-2-ethylhexyl phthalate are
also used in residential building materials
such as floorings, paints, carpet backings,
adhesives, and wallpaper and in PVC products
such as auto parts and interiors (ATSDR
1995, 2000). Although the volatility of phtha-
lates is relatively low, studies have shown that
phthalates are present in residential indoor air
(Rudel et al. 2003).
Human exposure to phthalates can occur
via ingestion, inhalation, and dermal routes,
as well as through parenteral exposure from
medical devices containing phthalates.
Currently, no human data on the propor-
tional contribution of the various sources of
phthalates to human body burden are avail-
able. Until recently, the primary exposure of
the general population to phthalates was
believed to result from ingestion of foods,
especially fatty foods such as milk, butter, and
meats. Recent data show that the low-molec-
ular-weight phthalates (DEP, DBP, BBzP)
may also be dermally absorbed and that the
more volatile phthalates can be inhaled
(ATSDR 1995, 2001).
The need for site-speciﬁc dosage medica-
tions has led to the use of enteric coatings
(Ashford and Fell 1994; Marvola et al. 1999).
Enteric-coated medications remain intact in the
stomach and release the active ingredients of
the underlying medication core into the lower
part of the small intestine or in the colon.
Enteric coatings generally consist of various
polymers, such as cellulose acetate phthalate,
cellulose acetate butyrate, ethylcellulose, poly-
vinyl acetate phthalate, and methacrylate
copolymers. These polymer coatings are plasti-
cized with compounds such as triethyl citrate,
dibutyl sebacate, and phthalates such as DEP
and DBP (Frohoff-Hulsmann et al. 1999;
Harris and Ghebre-Sellassie 1989). DEP and
DBP metabolize to MEP and MBP, respec-
tively, which can be measured in urine. In addi-
tion to tablets and capsules, other medications
and preparations may contain phthalates as
plasticizers. Speciﬁcally, cellulose acetate–free
ﬁlms for transdermal use may contain DBP as a
plasticizer (Rao and Diwan 1997).
The patient’s urinary phthalate concentra-
tions were compared with the concentrations
measured for the Second National Report on
Human Exposure to Environmental Chemicals
(CDC 2003; Table 1). CDC (2003) reported
data on phthalate monoester levels from partici-
pants in NHANES 1999–2000. NHANES is
an ongoing survey designed to measure the
health and nutrition status of the civilian non-
institutionalized U.S. population [National
Center for Health Statistics (NCHS) 2003].
The samples in the present study and the
NHANES 1999–2000 samples were analyzed
by the same CDC laboratory.
Compared with the NHANES 1999–2000
data set, the patient’s urinary MEP, MEHP,
and MBzP levels were unremarkable.
However, the patient’s concentration of MBP
in urine was two orders of magnitude higher
than the U.S. population 95th percentile for
males reported in the NHANES 1999–2000
data set. To date, the highest estimated DBP
exposure in a subset of the U.S. population,
speciﬁcally women of childbearing age (Kohn
et al. 2000), was considered more than two
orders of magnitude lower than the lowest no
observable adverse effect level (NOAEL) of
DBP from animal studies (Mylchreest et al.
2002). Our results suggest that medications
taken chronically can contribute to DBP expo-
sure that approaches the NOAEL measured in
animal studies. Further research is necessary to
determine whether any health risks are associ-
ated with human exposure to high levels
of MBP.
Our results suggest that in some circum-
stances individuals may be highly exposed to
phthalates. Therefore, in epidemiologic stud-
ies designed to determine predictors of expo-
sure to phthalates or potential health risks of
phthalates, a detailed assessment of medica-
tion use is important. Because phthalates may
be used in a variety of medications, a com-
plete record of all medications used and the
date the prescription was ﬁlled are needed to
begin to describe human exposure. The list of
medications should include medications
taken by all routes, including orally, nasally,
subgingivally, ophthalmologically, dermally,
intravenously, or by inhalation.
Conclusion
In the present study, we identiﬁed an individ-
ual with a urinary MBP level two orders of
magnitude higher than the U.S. population
95th percentile and linked this unusually high
urinary MBP concentration with the use of a
specific medication that contained DBP.
However, because this is a case report on a
single patient, replication of this finding in
other populations is needed to definitively
conclude that the medication was the main
contributor to the very high urinary concen-
tration of MBP. Additionally, further research
is needed to determine the proportional con-
tribution of medications, as well as other con-
sumer products, to a person’s total phthalate
burden. Adding to the complexity of appor-
tioning sources of phthalates is that individu-
als may be exposed orally as well as by
inhalation or dermal routes. When databases
on consumer products and foods containing
phthalates become available, these databases
should be linked with levels of urinary phtha-
lates measured in ongoing epidemiologic
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Table 1. Concentrations [ng/mL (µg/g creatinine)] of MEP, MBP, MBzP, and MEHP in the patient compared
with selected demographic groups in NHANES 1999–2000. 
NHANES 1999–2000
Phthalate Males Adults
metabolite  Patient Median 95th percentile Median 95th percentile
MEP 443.7 (162.6) 54 (120) 3,480 (1,940) 180 (154) 3,480 (2,170)
MBP 16,868 (6,180) 23.1 (17.0) 115 (63.6) 23.0 (19.5) 142 (91.0)
MBzP 9.3 (3.4) 17.7 (12.3) 108 (73.5) 13.8 (12.1) 86.3 (57.2)
MEHP 3.0 (1.1) 3.40 (2.76) 25.3 (21.6) 3.00 (2.98) 22.4 (17.5)investigations. Until this time, individual case
reports such as this one will provide clues on
relevant sources of human exposure and their
potential contribution to total body burden.
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